Equity incl. NCI
Balance – as of period end · $M
Q1 2024
809$M
All values (16)
| Period | Value ($M) | Status |
|---|---|---|
| Q2 2026 | 1,726 | reported |
| Q1 2026 | 1,494 | reported |
| Q4 2025 | 1,364 | reported |
| Q3 2025 | 1,272 | reported |
| Q2 2025 | 1,136 | reported |
| Q1 2025 | 1,042 | reported |
| Q4 2024 | 965 | reported |
| Q3 2024 | 890 | reported |
| Q2 2024 | 845 | reported |
| Q1 2024 | 809 | reported |
| Q4 2023 | −98 | reported |
| Q3 2023 | −117 | reported |
| Q2 2023 | −117 | reported |
| Q1 2023 | −100 | reported |
| Q4 2022 | −85 | reported |
| Q4 2021 | None | error |
26 periods without value hidden · Show gaps with reason · CSV with all sources · Technical ID: equity_total
More metrics for Astera Labs
Income statement
Balance sheet
Revenue by segment/product/region
Sources & calculation
- Value
- $809M
- Period
- Q1 2024, ended Mar 31, 2024 · as of Mar 31, 2024 (balance as of date, not a sum)
- Source
- 10-Q, filed May 8, 2024 · 0001736297-24-000006
- Location
- us-gaap:StockholdersEquity
- Confidence
- 1. – directly from an XBRL fact in the filing (or calculated exactly from it)
Versions
| v1 | $809M | May 8, 2024 | 10-Q 0001736297-24-000006 | reported · confidence 1. · current |